CAR-T Meeting 2021

Myeloma Patients Europe: collaborating on projects to benefit the myeloma community 2:49
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community
Ananda Plate • 11 Feb 2021
CAR T-cells in adult ALL 4:13
CAR T-cells in adult ALL
Arnon Nagler • 1 Feb 2021
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1 2:13
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1
Anna Sureda • 9 Feb 2021
The journey of CAR-T therapy from hematological malignancies to solid tumors 2:47
The journey of CAR-T therapy from hematological malignancies to solid tumors
Concetta Quintarelli • 4 Feb 2021
NK-CAR immunotherapy: where are we now? 1:41
NK-CAR immunotherapy: where are we now?
Concetta Quintarelli • 4 Feb 2021
The importance of partnering with patient organizations 3:48
The importance of partnering with patient organizations
Ananda Plate • 11 Feb 2021
Highlights from the 3rd European CAR T-cell Meeting 1:08
Highlights from the 3rd European CAR T-cell Meeting
Anna Sureda • 9 Feb 2021
CAR T-cells in myeloma: patients’ perspective 1:52
CAR T-cells in myeloma: patients’ perspective
Ananda Plate • 11 Feb 2021
Novel strategies to optimize CAR T-cell therapy 4:31
Novel strategies to optimize CAR T-cell therapy
Arnon Nagler • 1 Feb 2021
Management of CAR-T related side effects 1:50
Management of CAR-T related side effects
Ibrahim Yakoub-Agha • 4 Feb 2021
Progression of CAR-T trials in China 2:19
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
Infection prevention in patients receiving CAR T-cells 3:19
Infection prevention in patients receiving CAR T-cells
Joshua Hill • 10 Feb 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies 3:30
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
Cytopenias post-CAR T-cell therapy 4:10
Cytopenias post-CAR T-cell therapy
Ibrahim Yakoub-Agha • 4 Feb 2021
CAR-T trials to watch in China 3:21
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021
Infectious complications after CAR T-cell therapy 2:02
Infectious complications after CAR T-cell therapy
Joshua Hill • 10 Feb 2021
The content of VJRegenMed is intended for healthcare professionals